June 27, 2022

Medical Trend

Medical News and Medical Resources

Monoclonal antibody Bebtelovimab neutralizes all isoforms of Omicron variants

Monoclonal antibody Bebtelovimab neutralizes all isoforms of Omicron variants



 

Monoclonal antibody Bebtelovimab neutralizes all isoforms of Omicron variants.

 

Recently, a research paper on “Antibody evasion properties of SARS-CoV-2 Omicron sublineages” was published in “Nature”.

After experimenting with 19 monoclonal antibodies, the study found that only the bebtelovimab ( LY-COV1404 ) antibody can adequately neutralize all subtypes of the omicron variant .

These findings are part of a recent analysis by the team that showed that the three subtypes of Omicron mutated to the same extent as wild-type SARS-CoV-2 (SARS-CoV-2) and reduced the risk of mRNA vaccines Similar comparability in potency .

 

Monoclonal antibody Bebtelovimab neutralizes all isoforms of Omicron variants

 

 

After confirming the Omicron BA.1 mutant, the authors continued to monitor two clades where further variants were found: BA.1+ R346K and BA.2 .

The BA.1 + R346K subtype accounts for about 40% of the present global Omicron sequences and 35-60% in New Zealand, the UK and the US.

The BA.2 subtype, which accounts for about 10% of the global Omicron sequence, is increasing in prevalence and has become predominant in Denmark, India, and South Africa.

 

In addition, the authors investigated the sensitivity of each subtype of Omicron to neutralizing sera from individuals previously infected with wild-type 2019-nCoV (10 individuals), vaccinated with Pfizer-BioNTech (13 individuals), or Modder NA (12 people) vaccine individuals, and individuals who received any of the above mRNA vaccines as booster shots (15 people).

The authors found that the neutralizing activity of serum for BA.1 + R346K and BA.2 subtypes was significantly lower than that of wild-type 2019-nCoV, and the degree of decline was comparable to that of BA.1 previously reported.

However, the reduction in neutralizing activity was less pronounced in the sera of booster-vaccinated individuals.

 

Monoclonal antibody Bebtelovimab neutralizes all isoforms of Omicron variants

(Figure 1. BA.2 shows a serum neutralization profile similar to the BA.1 subtype.)

 

In laboratory experiments against 19 monoclonal antibodies, the authors found that BA.2 was significantly resistant to 17 of them. This includes a 27-fold decrease in the activity of sotrovimab, which retains decent activity against both BA.1 and BA.1 + R246K. Of the other two antibodies, cilgavimab (alone or in combination with tixagevimab) retained activity against BA.2 but was ineffective against BA.1. Only the recently approved bebtelovimab is effective against all three subtypes of Omicron.

 

Monoclonal antibody Bebtelovimab neutralizes all isoforms of Omicron variants

(Figure 2. BA.2 has different resistance to monoclonal antibodies)

 


The team concluded in the paper that the emergence of new coronavirus variants has reduced treatment options, and new strategies must continue to be developed to control the new coronavirus.

 

 

 

Monoclonal antibody Bebtelovimab neutralizes all isoforms of Omicron variants

(source:internet, reference only)


Disclaimer of medicaltrend.org